Ganglionic blockers were once widely used in the management of essential hypertension, and they constituted an important advance in the treatment of that disease. Unfortunately, the development of tolerance to these drugs and their numerous undesirable side effects resulting from their nonselective ganglion-blocking properties led to a decline in their use. They have now been completely replaced by more effective and less toxic drugs. They do, however, retain some usefulness in the emergency treatment of hypertensive crisis.
Was this article helpful?